[CAS NO. 113906-27-7] PNU-74654
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [113906-27-7]
Catalog
SLK-S8429
Brand
Selleck
CAS
113906-27-7
DESCRIPTION [113906-27-7]
Overview
| MDL | MFCD12912438 |
|---|---|
| Molecular Weight | 320.34 |
| Molecular Formula | C19H16N2O3 |
| SMILES | O=C(N/N=C/C1=CC=C(C)O1)C2=CC=CC=C2OC3=CC=CC=C3 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1217 mL | 15.6084 mL | 31.2168 mL |
| 5 mM | 0.6243 mL | 3.1217 mL | 6.2434 mL |
| 10 mM | 0.3122 mL | 1.5608 mL | 3.1217 mL |
| 50 mM | 0.0624 mL | 0.3122 mL | 0.6243 mL |
Description
PNU-75654 disrupts the via inhibition of the interaction (KD50=450 nM) between β-catenin and Tcf4.
Targets
| Wnt/β-catenin [1] (Cell-free assay) |
| 450 nM(Kd) |
In vitro
The PNU-74654 (PNU) compound is a non-FDAapproved drug which prevents that Tcf from binding to beta-catenin, acting as a Wnt/beta-catenin antagonist. In NCI-H295 cells,PNU-74654 significantly decreases cell proliferation 96 h after treatment, increases early and late apoptosis, decreases nuclear betacatenin accumulation, impairs CTNNB1/beta-catenin expression and increases betacatenin target genes 48 h after treatment. No effects are observed on HeLa cells. In NCI-H295 cells, PNU-74654 decreases cortisol, testosterone and androstenedione secretion 24 and 48 h after treatment. Additionally, in NCI-H295 cells, PNU-74654 decreases SF1 and CYP21A2 mRNA expression as well as the protein levels of STAR and aldosterone synthase 48 h after treatment. In Y1 cells, PNU-74654 impairs corticosterone secretion 24 h after treatment but does not decrease cell viability.
References
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.